MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-GJ-22-0015106
Globela Pharma Private Limited - pharma in Surat, Gujarat, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹295.59 Cr
▲ 13% YoY
Net profit · FY 2025
₹5.89 Cr
Net margin 2%
EBITDA · FY 2025
₹36.85 Cr
EBITDA margin 12.5%
Authorised capital
₹58 Cr
Registered with MCA
Paid-up capital
₹56.92 Cr
Issued & subscribed
Open charges
₹168.62 Cr
Satisfied ₹16 Cr
Company age
20 yrs
Est. 2006
Employees · EPFO
150
Provident fund records
About Globela Pharma Private Limited
Data last updated:
Globela Pharma Private Limited is a private limited company based in Surat, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 08 February 2006 and has been in existence for over 20 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U24230GJ2006PTC047699. Its GSTIN is 24AACCG5247N1ZE (Gujarat).
The company has an authorised share capital of ₹58 Cr and a paid-up capital of ₹56.92 Cr. It is led by directors including Bhanubhai Shambhubhai Vaghashia (Managing Director) and Mayur Anand Sirdesai.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Plot No. 357 – 358 Road No. 3 GIDC Sachin, Surat, Gujarat, India – 394230.
As per the financials filed for FY 2025, the company reported a revenue of ₹295.59 Cr, a growth of 13% compared to the previous year. For the same year it recorded a net profit of ₹5.89 Cr (net margin 2%) and EBITDA of ₹36.85 Cr (EBITDA margin 12.5%). Revenue has grown at a compounded annual rate (CAGR) of 22% over three years and 27% over five years.
The company has about 150 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
The company is associated with 1 brand: Globela Pharma. As per MCA filings, the company has open charges of ₹168.62 Cr and satisfied charges of ₹16 Cr on record. Court records list 22 cases involving the company, including 8 filed by the company and 14 filed against it; 4 cases are pending. The company has 8 deals on record (5 secondary share transfers, 3 funding rounds), with disclosed funding of ₹84.31 Cr; the latest was in September 2021. Its 8 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Ciron Drugs and Pharmaceuticals Private Limited with revenue of ₹304.93 Cr. The company has 8 MSME Form 1 returns on record between 2019 and 2024, listing 459 overdue payments to 75 micro and small suppliers.
Globela Pharma Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-22-0015106). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website globelapharma.com.
Company details
CIN U24230GJ2006PTC047699
Registration Number 047699
Incorporation Date 08 February 2006
ROC Ahmedabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-GJ-22-0015106
Key People
Bhanubhai Shambhubhai Vaghashia Managing Director Mayur Anand Sirdesai Director Pietro Ermanno Stefanutti Director Recognitions & Rankings of Globela Pharma
Contact details
Globela Pharma Private Limited's registered office is in Surat, Gujarat. Its website is globelapharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressPlot No. 357 – 358 Road No. 3 GIDC Sachin, Surat, Gujarat, India – 394230
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Globela Pharma Private Limited, buy the company report.
Comprehensive company report
Globela Pharma Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Globela Pharma operates one associated brand: Globela Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Finished formulations like tablets, capsules, syrups, and injectables are manufactured. | globelapharma.com |
Business activity
The main business activity of Globela Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Globela Pharma Private Limited, buy the company report.
Financials of Globela Pharma Private Limited
FY 2024 filings availableGlobela Pharma Private Limited reported revenue of ₹295.59 Cr (up 13% YoY) for FY 2025.
Revenue · FY 2025
₹295.59 Cr ▲ 13%
Net profit · FY 2025
₹5.89 Cr margin 2%
EBITDA · FY 2025
₹36.85 Cr margin 12.5%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 13%
3 years · compounded
▲ 22%
5 years · compounded
▲ 27%
EBITDA CAGR growth
1 year
▲ 68%
3 years · compounded
▲ 8%
5 years · compounded
▲ 21%
Revenue has grown at a compounded annual rate (CAGR) of 27% over five years, including 13% growth in the latest year. EBITDA rose 68% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹36.85 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹5.89 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 12.5% | ||||
| Net Profit Margin | 2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Globela Pharma Private Limited, buy the company report.
Board of directors of Globela Pharma Private Limited
Globela Pharma has 5 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mayur Anand Sirdesai Also directs: Sicp Investment Advisors India LLP, Emil Pharmaceutical Industries Private Limited, Cyrix Healthcare Private Limited and 4 more | Director | 23 Sep 2021 | 5 Years 1 Months | Current |
| Pietro Ermanno Stefanutti | Director | 13 Jan 2022 | 4 Years 9 Months | Current |
| Bhanubhai Shambhubhai Vaghashia Also directs: Globela Industries Private Limited | Managing Director | 08 Feb 2006 | 20 Years 9 Months | Current |
| Priyank Vaghashia Also directs: Globela Industries Private Limited, Globela Biotech LLP | Director | 23 Sep 2021 | 5 Years 1 Months | Current |
| Urmilaben Bhanubhai Vaghasiya | Director | 25 Oct 2010 | 16 Years 0 Months | Current |
Peer comparison
Globela Pharma Private Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Ciron Drugs and Pharmaceuticals Private Limited | ₹304.93 Cr (FY 2024) | 15.0% | Mumbai, Maharashtra, India | |||
| Aagya Biotech Private Limited | ₹298.87 Cr (FY 2024) | -8.0% | Roorkee, Uttarakhand, India | |||
| Somerset Therapeutics Private Limited | ₹297.65 Cr (FY 2025) | 35.0% | Bangalore, Karnataka, India | |||
| Biomatrix Healthcare Private Limited | ₹295.64 Cr (FY 2025) | 12.0% | Ahmedabad, Gujarat, India | |||
| Globela Pharma Private Limitedthis company | ₹295.59 Cr (FY 2025) | ₹5.89 Cr | 2% | 13.0% | 150 | Surat, Gujarat, India |
| Ravenbhel Health Care Private Limited | ₹290.95 Cr (FY 2025) | 16.0% | Jammu, Jammu and Kashmir, India | |||
| Agio Pharmaceuticals Limited | ₹287.95 Cr (FY 2025) | 29.0% | Mumbai, Maharashtra, India | |||
| Gracure Pharmaceuticals Limited | ₹287.44 Cr (FY 2025) | 27.0% | New Delhi, Delhi, India | |||
| Pinnacle Life Science Private Limited | ₹286.72 Cr (FY 2023) | -2.0% | Baddi, Himachal Pradesh, India |
To see the full peer comparison of Globela Pharma Private Limited, buy the company report.
Auditor
Globela Pharma Private Limited is audited by MSKA & Associates for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MSKA & Associates | FY 2024 | 105047W |
Shareholding
The shareholding of Globela Pharma Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Globela Pharma Private Limited, buy the company report.
Charges & borrowings
Open charges
₹168.62 Cr
Satisfied charges
₹16 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 05 Aug 2024 | 100967171 | Sidbi | ₹7.35 Cr | Open | |
| 06 May 2022 | 100568822 | Axis Bank Limited | ₹22.06 Cr | Open | |
| 25 Mar 2022 | 100554236 | Axis Bank Limited | ₹54.47 Cr | Open | |
| 28 Mar 2017 | 100091989 | Axis Bank Limited | ₹42.37 Cr | Open | |
| 29 Nov 2016 | 100065045 | Axis Bank Limited | ₹42.37 Cr | Open |
To see the full charge records of Globela Pharma Private Limited, buy the company report.
Total charge records: 10 View all charges
Deals & funding
Globela Pharma Private Limited has 8 deals on record (5 secondary share transfers, 3 funding rounds), with disclosed funding of ₹84.31 Cr; the latest was in September 2021.
Total deals
8
Secondary share transfers
5
Funding rounds
3
Disclosed funding
₹84.31 Cr
Deals on record (5 of 8)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2021 | Funding round | ₹81.9 Cr | Investors: Somerset Indus Capital Partners, ACP India Co-Invest LLP, 2 individuals |
| Nov 2015 | Secondary share transfer | Undisclosed | Buyer: 3 individuals Seller: 4 individuals |
| Mar 2012 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Oct 2011 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2011 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: an individual |
To see the full deal history of Globela Pharma Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Globela Pharma Private Limited has 22 court cases on record: 8 filed by Globela Pharma, 14 filed against it. 4 cases are pending and 18 are disposed.
Total cases
22
Filed by the company
8
Filed against the company
14
Pending
4
Disposed
18
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 15 | 12 | 4 |
| High courts | 7 | 2 | 0 |
Cases on record (5 of 22)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, SURAT, Gujarat | Court case (TMSUIT) | Filed against the company by Novartis Healthcare Pvt. Limited and 1 other | Disposed |
| Bombay High Court | Arbitration matter | Filed against the company by Mol Chem Limited | Disposed |
| High Court, GUJARAT | Court case (CR.MA) | Filed against the company by Cornileus Pharmaceuticals Pvt.Ltd and 3 others | Disposed |
| District court, West, Delhi | Criminal case | Filed against the company by Union of India | Pending |
| District court, Thiruvananthapuram, Kerala | Court case (Crl.MP(Complaint)) | Filed against the company by State Represented by Chief Inspector Drugs Intelligence Squad,Kerala | Pending |
To see the full case history of Globela Pharma Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Globela Pharma Private Limited has 8 MSME Form 1 returns on record between 2019 and 2024, listing 459 overdue payments to 75 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 75)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Sheth Impression LLP | |||
| Yash Packaging | |||
| Sigachi Industries Limited | |||
| B.S. Mehra Sons Pvt Ltd | |||
| an individual supplier |
To see the full MSME payment records of Globela Pharma Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Globela Pharma has 2 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
2
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Globela Industries Private Limited | U24304GJ2020PTC116892 | |
| Globela Laboratories Private Limited | U24304GJ2022PTC129637 |
To see the full group structure of Globela Pharma Private Limited, buy the company report.
Employees & EPFO
Globela Pharma Private Limited has a workforce of 150 employees on its EPFO records as of Sep 23, 2025, across 1 active EPFO establishment.
Employee count
150
Active EPFO establishments
1
Employee growth
4.17%
GST
Globela Pharma has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 24AACCG5247N1ZE | Gujarat | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Globela Pharma Private Limited, buy the company report.
Recent activity
Globela Pharma Private Limited has 12 board changes on record since 2006: 5 appointments and 7 cessations. The latest: Pietro Ermanno Stefanutti ceased to be Additional Director on 30 Sep 2022.
AGM
Globela Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Charges
A charge with Sidbi amounted to Rs. 7.35 Cr with Charge ID 100967171 was registered on 05 Aug 2024.
Filing
Globela Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Ahmedabad.
Charges
A charge with Axis Bank Limited of Rs. 22.06 Cr registered on 06 May 2022 with Charge ID 100568822 was modified on 05 Mar 2024.
Charges
A charge with Axis Bank Limited of Rs. 54.47 Cr registered on 25 Mar 2022 with Charge ID 100554236 was modified on 09 Jan 2024.
Charges
A charge with Axis Bank Limited of Rs. 42.37 Cr registered on 29 Nov 2016 with Charge ID 100065045 was modified on 19 Dec 2023.
Charges
A charge with Axis Bank Limited of Rs. 42.37 Cr registered on 28 Mar 2017 with Charge ID 100091989 was modified on 04 Dec 2023.
Ceased
Pietro Ermanno Stefanutti ceased to be Additional Director.
Charges
A charge with Axis Bank Limited amounted to Rs. 22.06 Cr with Charge ID 100568822 was registered on 06 May 2022.
Charges
A charge with Axis Bank Limited amounted to Rs. 54.47 Cr with Charge ID 100554236 was registered on 25 Mar 2022.
Appointed
Pietro Ermanno Stefanutti was appointed as Director.
Charges
A charge registered on 04 Nov 2020 via Charge ID 100390217 with Axis Bank Limited was fully satisfied on 11 Oct 2021.
24 earlier events are in the company report.
Frequently asked questions
Globela Pharma is an active private limited company based in Surat, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 08 February 2006 (20+ years old) and is registered under CIN U24230GJ2006PTC047699.
Globela Pharma has 5 current directors:
- Bhanubhai Shambhubhai Vaghashia - Managing Director
- Mayur Anand Sirdesai - Director
- Pietro Ermanno Stefanutti - Director
- Priyank Vaghashia - Director
- Urmilaben Bhanubhai Vaghasiya - Director
The latest financial statements of Globela Pharma on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Globela Pharma is 24AACCG5247N1ZE, registered in Gujarat.
The CIN (Corporate Identification Number) of Globela Pharma is U24230GJ2006PTC047699. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Globela Pharma has 22 court cases on record: 8 filed by the company and 14 filed against it. 4 are pending. Most are in the district courts.
Globela Pharma was incorporated on 08 February 2006, making it 20+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Globela Pharma has 8 deals on record (5 secondary share transfers, 3 funding rounds), with disclosed funding of ₹84.31 Cr; the latest was in September 2021.
The peers of Globela Pharma by revenue are Ciron Drugs and Pharmaceuticals Private Limited, Aagya Biotech Private Limited, Somerset Therapeutics Private Limited, Biomatrix Healthcare Private Limited, Ravenbhel Health Care Private Limited and 3 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Pietro Ermanno Stefanutti ceased to be Additional Director on 30 Sep 2022. Pietro Ermanno Stefanutti was appointed as Director on 13 Jan 2022. Mayur Anand Sirdesai was appointed as Director on 23 Sep 2021. Globela Pharma has 12 board changes on record in total.
Yes, Globela Pharma is registered as a medium enterprise under Udyam registration (number: UDYAM-GJ-22-0015106).
Globela Pharma has 8 MSME Form 1 returns on record between 2019 and 2024, listing 459 overdue payments to 75 micro and small suppliers. The latest return was filed on 05 May 2024.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages